China Medical System (HKG:0867, SGX:8A8), through its units, entered an agreement with Novartis Pharma Services to distribute Lucentis and Beovu, a Monday Hong Kong bourse filing said.

Under the contract, the pharma firm will import, distribute, sell, and promote the products in China, excluding Hong Kong, Macao, and Taiwan, for five years.

Lucentis has been approved to treat multiple ocular neovascular diseases in China since 2011, while Beovu is approved to treat diabetic macular edema.